These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 2702800)

  • 1. A phase I-II trial of 4'-deoxydoxorubicin (esorubicin) in refractory or relapsed acute leukemia.
    Dutcher JP; Riggs CE; Strauman JJ; Link B; Wiernik PH
    Clin Pharmacol Ther; 1989 Apr; 45(4):424-8. PubMed ID: 2702800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and phase I evaluation of esorubicin (4'-deoxydoxorubicin) by continuous infusion over forty-eight hours in patients with leukemia.
    Kreis W; Rottach C; Budman DR; Chan K; Schulman P; Allen SL; Weiselberg L; Vinciguerra V
    Cancer Res; 1988 Oct; 48(19):5580-4. PubMed ID: 3166400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of esorubicin (4' deoxydoxorubicin) in cancers of the breast, colon, kidney, lung and melanoma.
    Braich TA; Salmon SE; Robertone A; Alberts DS; Jones SE; Miller TP; Garewal HS
    Invest New Drugs; 1986; 4(3):269-74. PubMed ID: 3818231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial with 4'-deoxydoxorubicin (esorubicin).
    Rozencweig M; Crespeigne N; Kenis Y
    Invest New Drugs; 1983; 1(4):309-13. PubMed ID: 6678877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
    Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Esorubicin (4'-deoxydoxorubicin, NSC 267469) in advanced breast cancer. A phase II study of the CALGB.
    Muss HB; Van Echo D; Korzun AH; Henderson IC; Campbell T; Vogelzang NJ; Rice MA; Wood W
    Am J Clin Oncol; 1990 Jun; 13(3):233-7. PubMed ID: 2346128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Phase II trial of mitoxantrone in patients with relapsed and refractory acute leukemia].
    Sampi K; Kaneko Y; Maseki N; Kumai R; Sakurai M; Hattori M
    Gan To Kagaku Ryoho; 1985 Jul; 12(7):1453-7. PubMed ID: 4015120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of esorubicin (4'deoxydoxorubicin).
    Garewal HS; Robertone A; Salmon SE; Jones SE; Alberts DS; Brooks R
    J Clin Oncol; 1984 Sep; 2(9):1034-9. PubMed ID: 6470753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of 4'-deoxydoxorubicin in advanced colorectal cancer.
    Falkson G; Vorobiof DA
    Invest New Drugs; 1986; 4(2):165-9. PubMed ID: 3733376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical cardiotoxicity of esorubicin (4'-deoxydoxorubicin,DxDx): prospective studies with serial gated heart scans and reports of selected cases. A Cancer and Leukemia Group B report.
    Ringenberg QS; Propert KJ; Muss HB; Weiss RB; Schilsky RL; Modeas C; Perry MC; Norton L; Green M
    Invest New Drugs; 1990 May; 8(2):221-6. PubMed ID: 2166722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human pharmacokinetics of esorubicin (4'-deoxydoxorubicin).
    Dodion P; Davis TA; Rozencweig M; Crespeigne N; Kenis Y; Bachur NR
    Invest New Drugs; 1985; 3(4):361-8. PubMed ID: 4086243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of esorubicin (4'-deoxydoxorubicin) in advanced epithelial carcinoma of the ovary: a Gynecologic Oncology Group study.
    McGuire WP; Blessing JA; Berman ML
    Invest New Drugs; 1989 Nov; 7(4):333-6. PubMed ID: 2557300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of esorubicin (4'-deoxydoxorubicin) in locally advanced or metastatic head and neck carcinoma.
    Frustaci S; Gasparini G; Veronesi A; Tirelli U; Pacciarini MA; Crivellari D; Zagonel V; Monfardini S
    Invest New Drugs; 1987; 5(3):307-9. PubMed ID: 3667167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II evaluation of esorubicin (4'deoxydoxorubicin) in pancreatic adenocarcinoma: a Southwest Oncology Group study.
    Vaughn CB; Salmon SE; Fleming TR
    Invest New Drugs; 1990 Feb; 8(1):81-5. PubMed ID: 2188929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemically targeted therapy of refractory leukemia and myeloid blast crisis of chronic granulocytic leukemia with Tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
    Tricot G; Weber G
    Anticancer Res; 1996; 16(6A):3341-7. PubMed ID: 9042309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of CI-973, a platinum analogue, in refractory or relapsed acute leukemia.
    Kantarjian HM; Beran M; O'Brien S; Robertson L; Siddik Z; Yoshida M; Yang LY; Rios MB; Keating MJ; Meyer M
    Leukemia; 1996 Mar; 10(3):396-401. PubMed ID: 8642853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
    Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
    Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
    Feldman EJ; Alberts DS; Arlin Z; Ahmed T; Mittelman A; Baskind P; Peng YM; Baier M; Plezia P
    J Clin Oncol; 1993 Oct; 11(10):2002-9. PubMed ID: 8410125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of 4'-deoxydoxorubicin (esorubicin) in hormone resistant prostate cancer.
    Braich T; Ahmann FR; Garewal HS; Robertone A; Salmon SE
    Invest New Drugs; 1986; 4(2):193-6. PubMed ID: 3733379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical studies with new anthracyclines: epirubicin, idarubicin, esorubicin.
    Hurteloup P; Ganzina F
    Drugs Exp Clin Res; 1986; 12(1-3):233-46. PubMed ID: 3525075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.